Biotech Values

[DewDiligence]

I don't see Edurant amounting to much, with Btripla coming up in August, especially since edurant.com is registered to some guy in Greenfield, WI… who launches a drug without a .com website nowadays?

Excellent “right-brain” sleuthing and the kind of insight that biotech message boards were made for. Your prediction is confirmed by the sorry data cited in #msg-65585414.

p.s. If more investors would use the kind of right-brain skill you applied to Edurant in order to evaluate MNTA, they would readily see that Teva will not be getting FDA approval for generic Lovenox for a long time, if ever.